SPOTLIGHT: Cardiome delays analysis
There's plenty of buzz this morning about Cardiome Pharma, which announced that it is delaying an interim analysis on a key heart drug--vernakalant--so it can add data from more patients in the Phase IIb study. Analysts say the company is likely involved in partnership talks. Cardiome now expects to release the analysis in March. Release
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
